Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

757.39 +25.60 (+3.50%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Eli Lilly's Stock Keeps Looking Better and Better. Here's the Latest Reason Why.
Its rock-star therapy looks like it could be marketed as a preventative treatment. 
Via The Motley Fool
Eli Lilly Slashes Zepbound Weight Loss Vial Prices By Up To 50% To Boost Access
Eli Lilly launches low-dose Zepbound vials for weight loss, offering 2.5 mg and 5 mg options for self-pay patients. These vials, priced at a significant discount compared to other GLP-1 obesity drugs,... 
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Shareholders don't have too much to fear -- yet. 
Via The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited... 
Via Benzinga
Exploring The Competitive Space: Eli Lilly Versus Industry Peers In Pharmaceuticals
Via Benzinga
Check Out What Whales Are Doing With LLY
Via Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes. 
Via MarketBeat
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed. 
Via Benzinga
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
The new drugs this company is developing could be worth a lot more than the present market value of its stock. 
Via The Motley Fool
Mounjaro Scores Yet Another Win: Why Eli Lilly Is Still a Buy
The drugmaker looks unstoppable. 
Via The Motley Fool
If You Like Eli Lilly, Then You'll Love This Little-Known Specialty Manufacturing Stock
Jacobs Solutions stands to be a beneficiary of the red-hot weight loss movement fueling the pharmaceutical market. 
Via The Motley Fool
Prediction: These Will Be the Best-Performing S&P 500 Stocks of 2024
The S&P 500's top three at year-end could look a little different than they do now. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
AskSlim Market Week - Friday, Aug. 23
An analysis and commentary on the financial markets. 
Via Talk Markets
Why Apple Stock And This 'Recession-Proof' Leader Strengthen Market's Bull Case
What happens when you get rate cuts as a tech revolution is starting? An environment that's set to supercharge the stock market, says this expert. 
Via Investor's Business Daily
Stock Market Rallies As Powell Confirms Rate Cuts; Palo Alto, Cava, Target Jump: Weekly Review
Palo Alto and Cava were among the earnings winners. 
Via Investor's Business Daily
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
Kellanova and Fortinet are leading the S&P 500's August performance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Visualizing The World’s Top 25 Companies By Market Cap
The world’s top 25 companies by market capitalization. 
Via Talk Markets
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results 
Via News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Ozempic remains on top in the GLP-1 drug market -- but for how long? 
Via The Motley Fool
Eli Lilly Hits All-Time High, Gets Watchlist Trifecta: These Names Just Added To IBD 50, Other Top Stock Screens
Eli Lilly deserved landing on three top stock lists. The drug giant hit an all-time high Thursday and has surging earnings and revenue. 
Via Investor's Business Daily
Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
Eli Lilly's valuation may seem high right now, but with fast earnings growth, today's price could look like a deal in a few years. 
Via The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
This leading pharmaceutical stock is flying under the radar right now. 
Via The Motley Fool
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments. 
Via Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish... 
Via Benzinga
Topics Economy
Exposures Supply Chain
Asia Mixed, European Markets Advance; Gold Stays Near All Time High While Dollar Gains - Global Markets Today While US Slept
US stock markets close lower, breaking 8-day winning streak as investors pause before economic symposium. Energy stocks decline, consumer staples gain. 
Via Benzinga
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run. 
Via The Motley Fool
Why Eli Lilly Topped the Market on Tuesday
The company had very encouraging news to report about its hottest product. 
Via The Motley Fool
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Wall Street Eases, Bonds Rises, US Dollar Falls To 8-Month Low: What's Driving Markets Tuesday?
It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices traded in the red at around midday trading in New York. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.